LivaNova's (LIVN) Buy Rating Reaffirmed at Needham & Company LLC

LivaNova (NASDAQ:LIVN - Get Free Report)'s stock had its "buy" rating reaffirmed by equities research analysts at Needham & Company LLC in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $75.00 price objective on the stock. Needham & Company LLC's price objective indicates a potential upside of 41.51% from the stock's current price.

Several other brokerages also recently weighed in on LIVN. Stifel Nicolaus upped their target price on LivaNova from $70.00 to $72.00 and gave the stock a "buy" rating in a research note on Thursday, July 25th. StockNews.com upgraded shares of LivaNova from a "buy" rating to a "strong-buy" rating in a research report on Friday. Robert W. Baird raised their price target on shares of LivaNova from $66.00 to $72.00 and gave the company an "outperform" rating in a research note on Thursday, October 31st. Mizuho cut their price objective on LivaNova from $80.00 to $70.00 and set an "outperform" rating for the company in a research note on Thursday, October 31st. Finally, The Goldman Sachs Group initiated coverage on LivaNova in a research report on Friday, October 4th. They issued a "buy" rating and a $65.00 target price on the stock. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $69.17.

LivaNova Stock Performance

NASDAQ:LIVN traded up $1.19 during trading hours on Tuesday, reaching $53.00. The company had a trading volume of 631,105 shares, compared to its average volume of 620,765. The firm has a market cap of $2.88 billion, a PE ratio of 126.52 and a beta of 1.01. LivaNova has a 1-year low of $42.75 and a 1-year high of $64.47. The business's 50 day moving average price is $51.40 and its 200-day moving average price is $53.00. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87.

Institutional Investors Weigh In On LivaNova

Several hedge funds and other institutional investors have recently bought and sold shares of the company. BNP Paribas Financial Markets raised its stake in shares of LivaNova by 88.6% in the 1st quarter. BNP Paribas Financial Markets now owns 42,121 shares of the company's stock valued at $2,356,000 after acquiring an additional 19,783 shares during the period. Texas Permanent School Fund Corp raised its holdings in LivaNova by 1.3% in the first quarter. Texas Permanent School Fund Corp now owns 47,147 shares of the company's stock valued at $2,637,000 after acquiring an additional 620 shares in the last quarter. ProShare Advisors LLC lifted its stake in LivaNova by 4.7% in the first quarter. ProShare Advisors LLC now owns 12,378 shares of the company's stock worth $692,000 after acquiring an additional 561 shares during the last quarter. Entropy Technologies LP purchased a new stake in shares of LivaNova in the 1st quarter valued at approximately $295,000. Finally, State Board of Administration of Florida Retirement System raised its holdings in shares of LivaNova by 13.3% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 17,542 shares of the company's stock valued at $981,000 after purchasing an additional 2,060 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.